Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
cirtociclib
Cancer
Blueprint Medicines Corporation
P1
C
(36)
Ckd-512
Cancer
Chong Kun Dang Pharmaceutical
P1
C
(36)
cs08399
Cancer
Chipscreen Biosciences, Ltd.
P1
C
(36)
Divarasib
Cancer
Genentech, Inc.
P1
C
(36)
dl2
Cancer
Sun Pharma Advanced Research Company Limited
P1
C
(36)
dl3
Cancer
Sun Pharma Advanced Research Company Limited
P1
C
(36)
dl4
Cancer
Sun Pharma Advanced Research Company Limited
P1
C
(36)
dl5
Cancer
Sun Pharma Advanced Research Company Limited
P1
C
(36)
dxc006
Cancer
Hangzhou DAC Biotechnology Co., Ltd.
P1
C
(36)
e303
Cancer
Samsung Bioepis Co., Ltd.
P1
C
(36)
eos301984
Cancer
iTeos Therapeutics
P1
C
(36)
fda022 monoclonal antibody-drug conjugate
Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
P1
C
(36)
ff-10832
Advanced Solid Tumors
Fujifilm Pharmaceuticals U.S.A., Inc.
P1
C
(36)
ff-10832 gemcitabine liposome
Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
P1
C
(36)
FF 10850
Advanced Solid Tumors
Fujifilm Pharmaceuticals U.S.A., Inc.
P1
C
(36)
ff-10850 topotecan liposome
Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
P1
C
(36)
Fhnd5071
Cancer
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
P1
C
(36)
Fid-022
Cancer
Fulgent Pharma LLC.
P1
C
(36)
Forx-428
Cancer
FoRx Therapeutics AG
P1
C
(36)
fp008 for
Cancer
Zhuhai Fapon Biopharma Co., Ltd.
P1
C
(36)
fs-8002
Cancer
Shanghai Pushi Medical Science Co. Ltd
P1
C
(36)
gec255 tablets
Cancer
GenEros Biopharma Hangzhou Ltd
P1
C
(36)
gen1079
Cancer
Genmab
P1
C
(36)
Gen-725 Tablets
Cancer
Henan Genuine Biotech Co., Ltd.
P1
C
(36)
Gena-104A16
Cancer
Genome & Company
P1
C
(36)
Showing 251 to 275 of 423 assets
Previous
Page 11 of 17
Next